# EDGAR Filing Document

**Accession Number:** 0001533743
**File Stem:** 0001641172-25-019663
**Filing Date:** 2025-7
**Character Count:** 5161
**Document Hash:** f10ad9f1742c19c21cdc3343a33054d2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-019663.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001641172-25-019663

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250715

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250715

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Processa Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001533743
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 451539785
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39531
- **FILM NUMBER:** 251123955

**BUSINESS ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076
- **BUSINESS PHONE:** 443-776-3133

**MAIL ADDRESS:**
- **STREET 1:** 7380 COCA COLA DRIVE
- **STREET 2:** SUITE 106
- **CITY:** HANOVER
- **STATE:** MD
- **ZIP:** 21076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Heatwurx, Inc.
- **DATE OF NAME CHANGE:** 20111028

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): July 15, 2025**

Commission file number 001-39531

**PROCESSA PHARMACEUTICALS, INC.**

**(Exact name of Registrant as Specified in its Charter)**

---

| | |
|:---|:---|
| **Delaware** | **45-1539785** |
| **(State or Other Jurisdiction of <br> Incorporation or Organization)** | **(I.R.S. Employer <br> Identification Number)** |

---

---

| |
|:---|
| **601 21<sup>st</sup> Street** **, Suite 300, Vero Beach, FL 32960** |
| **(Address of Principal Executive Offices, Including Zip Code)** |

---

---

| |
|:---|
| **(772) 453-2899** |
| **(Registrant's Telephone Number, Including Area Code)** |

---

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common stock: Par value $.0001 | PCSA | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07. Submission of Matters to a Vote of Security Holders**

On June 30, 2025, Processa Pharmaceuticals, Inc. convened its Annual Shareholder Meeting at 1:00 PM EDT in Hanover, MD.

At that time, there were not present or represented by proxy a sufficient number of shares of the Company's Stock to constitute a quorum. The Company adjourned the meeting without conducting any business because a quorum was not present. The Company has now received by proxy a sufficient number of shares of the Company's common stock to constitute a quorum.

The meeting, which was adjourned until July 30, 2025, at 1:00 PM in Hanover, MD will now be reconvened on July 18, 2025, at 9:00 AM in Hanover, MD.

The Company will not change the record date of the Annual Meeting. Accordingly, only stockholders of record at the close of business on May 1, 2025, will be entitled to vote at the reconvened Annual Meeting.

Stockholders who have previously submitted their proxy or otherwise voted and who do not wish to change their vote do not need to take any action. The proposals for the meeting remain unchanged, and the proxy statement and other SEC filings are available on the SEC's website at www.sec.gov.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on July 15, 2025.

---

| | |
|:---|:---|
| PROCESSA PHARMACEUTICALS, INC. | PROCESSA PHARMACEUTICALS, INC. |
| Registrant | Registrant |
| By: | */s/ George Ng* |
|  | George Ng |
|  | Chief Executive Officer |

---